Check-Cap Ltd. (NASDAQ:CHEK) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Tuesday.
Other research analysts also recently issued reports about the stock. Maxim Group reissued a “buy” rating on shares of Check-Cap in a research report on Tuesday, May 30th. Zacks Investment Research raised shares of Check-Cap from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research report on Thursday, June 1st. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Check-Cap has a consensus rating of “Buy” and an average target price of $5.00.
Check-Cap (CHEK) opened at 1.84 on Tuesday. The firm’s market capitalization is $28.76 million. The company’s 50-day moving average is $1.94 and its 200-day moving average is $2.17. Check-Cap has a 52-week low of $1.08 and a 52-week high of $3.42.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://transcriptdaily.com/2017/07/18/check-cap-ltd-nasdaqchek-upgraded-to-hold-by-valuengine.html.
An institutional investor recently raised its position in Check-Cap stock. Knott David M boosted its stake in shares of Check-Cap Ltd. (NASDAQ:CHEK) by 1.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 162,871 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Knott David M owned about 1.05% of Check-Cap worth $349,000 as of its most recent SEC filing. Institutional investors own 13.35% of the company’s stock.
Check-Cap Company Profile
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.